Next-Generation CAR T-Cells to Cure Cancer

Gene Edited Off-the-shelf Immunotherapies:
A Future-defining Shift in Simplicity, Availability, and Cost-effectiveness

Learn more

TALEN® enables gene editing
at industrial scale

Gene editing will completely reshape molecular medicine within five years. Our flagship TALEN® technology provides us with the ability to rethink how we treat diseases altogether. Cells can be engineered with optimized features for cancer therapies, drug discovery, gene function studies, industrial biotechnology and more. It is the next transformative step in medicine.

Learn more

"Off-the-shelf" immunotherapies
that can work for the largest number of patients

Cellectis gene-edits “Chimeric Antigen Receptor” (CAR) T-cells from healthy donors into “off-the-shelf” immunotherapy product candidates that are designed to work for the largest number of patients. It’s the difference between being an off-the-shelf product and a service in which each treatment has to be custom-made. This same technology, developed by Cellectis, could help in designing therapies for many other diseases.

Learn more

Strong intellectual property,
global strategic partnerships.

18 years of innovation. 175 patent families. 163 granted patents and 737 applications. Global strategic partnerships with Allogene, Servier, and leading Universities all over the world.

Learn more